Patents by Inventor Jochen Genschel

Jochen Genschel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE TRANSTHYRETIN GENE
    Publication number: 20240011003
    Abstract: The present invention encompasses engineered meganucleases that bind and cleave a recognition sequence within a TTR gene. The present invention also encompasses methods of using such engineered meganucleases to make genetically-modified cells. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or nucleic acids encoding engineered meganucleases of the invention, and the use of such compositions for treatment of TTR-associated diseases, such as transthyretin amyloidosis.
    Type: Application
    Filed: August 20, 2021
    Publication date: January 11, 2024
    Applicant: Precision Biosciences, Inc.
    Inventors: Cassandra Gorsuch, Jochen Genschel, Janel Lape, Derek Jantz, James Jefferson Smith
  • OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20240000845
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.
    Type: Application
    Filed: September 5, 2023
    Publication date: January 4, 2024
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
  • Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
    Patent number: 11786554
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: October 17, 2023
    Assignee: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
  • OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20210113616
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.
    Type: Application
    Filed: April 11, 2019
    Publication date: April 22, 2021
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel